The therapeutic potential of Actinium-225-labeled CS1-specific single-domain antibodies for the treatment of Multiple Myeloma

Zoekresultaten

• Actief

  SRP50: SRP-Onderzoekszwaartepunt: Exploiting Peptides: Protein Binders, Modulators and Inhibitors for Imaging and Therapy [Exploit-PeptIT]

  Ballet, S., Caveliers, V., Hernot, S., Versées, W., Vinken, M., Muyldermans, S., Devoogdt, N., Bridoux, J. & Martin, C.

  1/03/19 → 30/09/25

  Project: Fundamenteel

  • Single-Domain Antibodies 100%
  • Neoplasms 14%
  • Radioisotopes 13%
  • Immunoglobulin Fragments 11%
  • Peptide 11%
• Afgelopen

  SRP62: SRP-Groeifinanciering: Single-domain antibody fragment (SdAb)-based TArgeted Radionuclide Therapy: STaRT programme

  Keyaerts, M., D'Huyvetter, M. & Neyns, B.

  1/03/19 → 30/09/24

  Project: Fundamenteel

  • Single-Domain Antibodies 100%
  • Immunoglobulin Fragments 57%
  • Radiopharmaceuticals 54%
  • Radioisotopes 46%
  • Kidney 44%

• SRP48: Strategic Research Programme: Cancer Cell Targeting in Myeloma and Melanoma (MyMe)

  Vanderkerken, K., Thielemans, K., Vanderkerken, K. & Breckpot, K.

  1/11/17 → 31/10/24

  Project: Fundamenteel

  • Single-Domain Antibodies 100%
  • Multiple Myeloma 90%
  • Neoplasms 43%
  • T-Lymphocytes 26%
  • Melanoma 16%

• ANI184: Nanobody-targeted radionuclide therapy and immune therapy: a perfect match in the area of combination therapy.

  Breckpot, K. & Keyaerts, M.

  1/01/17 → 31/12/21

  Project: Fundamenteel

  • Single-Domain Antibodies 100%
  • Radioisotopes 35%
  • Actinium-225 33%
  • Immunoglobulin Fragments 23%
  • Multiple Myeloma 16%